NCT01875705View on ClinicalTrials.gov

A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 21, 2013

Primary Completion Date

September 23, 2016

Study Completion Date

September 23, 2016

Conditions
Solid Tumor
Interventions
DRUG

GDC-0994

Escalating doses of GDC-0994 until maximum tolerated dose is reached

DRUG

GDC-0994

Recommended dose determined in Stage I-Dose Escalation phase, until disease progression

Trial Locations (4)

37203

Sarah Cannon Research Inst., Nashville

48201

Karmanos Can Inst, Detroit

94805

Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif

06520

Yale Cancer Center; Medical Oncology, New Haven

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT01875705 - A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter